Contributor:
Pam Ventola, PhD (Chief Science Officer)
Rare disease studies have little margin for error. When participant numbers are limited, even small sources of variability can make it harder to detect treatment effects and confidently interpret outcomes.
In a recent webinar, Cogstate’s Chief Science Officer, Pam Ventola, PhD, presented strategies to strengthen endpoint quality and improve signal detection in rare disease clinical trials, helping study teams maximize the value of every participant’s data and make better-informed decisions throughout the trial.
Here are three key takeaways:
1. A strong rater training strategy improves data consistency.
Rater variability can have a significant impact on signal detection in rare disease trials—making a thoughtful training strategy essential. Program-level rater training programs can improve consistency by certifying raters across multiple studies, reducing redundant training while easing the burden on sites. Training should also be tailored to the specific assessments used in the study to ensure raters administer them consistently and confidently.
For some studies, central rating offers another way to reduce variability by having cognitive and clinical outcome measures administered via telehealth (video or phone) by an independent team of highly qualified raters. Central raters are uniformly and regularly trained and calibrated to increase reliability, standardizations, and scoring accuracy for the clinical outcome assessments in your study. This approach gives sites rapid access to experienced professionals. It also allows participants to be assessed from their home, reducing site visits, and supporting faster and more diverse recruitment.
“In one rare disease program supported by Cogstate, just seven central raters completed 180 Vineland assessments, compared with 52 site-based raters who completed 130 assessments in a comparable study,” said Ventola. “While both studies achieved similar rater accuracy, the central rating model reduced the number of individuals collecting data, helping minimize variability and strengthen endpoint quality.”
See the poster data here.
2. Rare disease trials need eCOA designs that actively protect data quality.
In rare disease studies, eCOA design decisions can directly influence endpoint quality. Small configuration choices, such as how developmental starting points are handled or when branching logic is triggered, can affect data consistency over the course of a trial. When designed to meet the specific needs of a study, it becomes a valuable tool for improving data quality and reducing the risk of assessment errors.
“Thoughtful eCOA design is especially important for rare disease trials,” said Ventola. “Developmental assessments, for example, often rely on carefully defined starting points. Depending on the protocol and endpoint, the appropriate starting point may need to remain consistent throughout the study or be tailored to each participant. Getting this right is critical to ensuring reliable and comparable data.”
Other design features, such as basal and ceiling logic, automated scoring, skip logic, baseline-to-follow-up linking, and embedded scoring guidance, can further improve assessment consistency while reducing the burden on raters.
By incorporating these capabilities into the eCOA from the outset, study teams can enhance endpoint reliability and maximize the value of the data collected.
3. Reviewing every assessment isn’t practical. A risk-based approach focuses attention where problems are most likely to occur, combining targeted early review with analytics that flag unusual scoring patterns or unexpected changes over time.
Even with well-designed eCOA systems and comprehensive rater training programs, complex rare disease assessments require ongoing oversight to ensure data quality. Strategic data quality monitoring allows study teams to identify administration and scoring issues early, providing targeted feedback, retraining, and other interventions that improve rater performance and protect endpoint reliability throughout the trial.
“Rather than reviewing every assessment, a risk-based approach combines targeted review of early administrations with analytics-driven monitoring to focus attention where it is needed most,” said Ventola. “By using blinded data visualizations and programmatic flags informed by clinical expertise, study teams can identify unusual patterns, unexpected score changes, or potential assessment errors more efficiently, strengthening signal detection while making the best use of limited resources.”
Summary
In rare disease trials, every participant matters. The strongest studies reduce variability wherever possible, through better rater training, smarter assessment design, and targeted data quality oversight. Together, these approaches help study teams generate cleaner endpoint data and improve confidence in trial outcomes.
To learn more about these approaches and hear additional real-world examples from Dr. Ventola, watch the full webinar on demand.
